A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Dana-Farber Cancer Institute, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Queen Mary University of London, Barts Cancer Institute, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Instituto Nacional del Cáncer, The University of Texas MD Anderson Cancer Center, University of Colorado Anschutz, Washington University in St. Louis, Bristol-Myers Squibb (United States), Exelixis (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891290712